Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Current Assets (2016 - 2026)

Bio-Techne has reported Current Assets over the past 17 years, most recently at $637.4 million for Q4 2025.

  • For Q4 2025, Current Assets changed 0.44% year-over-year to $637.4 million; the TTM value through Dec 2025 reached $637.4 million, changed 0.44%, while the annual FY2025 figure was $608.3 million, 1.48% down from the prior year.
  • Current Assets for Q4 2025 was $637.4 million at Bio-Techne, up from $609.5 million in the prior quarter.
  • Over five years, Current Assets peaked at $648.6 million in Q3 2024 and troughed at $510.6 million in Q2 2021.
  • A 5-year average of $594.8 million and a median of $599.3 million in 2022 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: grew 18.6% in 2022 and later decreased 6.02% in 2025.
  • Year by year, Current Assets stood at $590.2 million in 2021, then dropped by 4.24% to $565.2 million in 2022, then rose by 4.5% to $590.6 million in 2023, then grew by 7.45% to $634.6 million in 2024, then grew by 0.44% to $637.4 million in 2025.
  • Business Quant data shows Current Assets for TECH at $637.4 million in Q4 2025, $609.5 million in Q3 2025, and $608.3 million in Q2 2025.